Metraipolis › archive › dc_89cd1f0afd42

FDA approval of copper histidinate (Zycubo) for Menkes disease: a therapeutic breakthrough in a rare pediatric neurodegenerative disorder — Europe PMC PMID:42254141

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42254141
DOI
10.1097/ms9.0000000000005071
License (as archived)
solo-consultazione
Archived
2026-11-03T02:29:51.446Z
SHA-256 of the archived text
2f9cde0fd307c0c8dd25cda829438ac8e4f34e05a3eb66c6fda052fda372f526
Stable URL of this page
https://metraipolis.com/documento/dc_89cd1f0afd42

How to cite

FDA approval of copper histidinate (Zycubo) for Menkes disease: a therapeutic breakthrough in a rare pediatric neurodegenerative disorder — Europe PMC PMID:42254141 — Europe PMC (en), https://europepmc.org/article/MED/42254141 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_89cd1f0afd42 (Metraipolis archive dc_89cd1f0afd42, sha256 2f9cde0fd307c0c8dd25cda829438ac8e4f34e05a3eb66c6fda052fda372f526)
BibTeX
@misc{dc89cd1f0afd42,
  title = {FDA approval of copper histidinate (Zycubo) for Menkes disease: a therapeutic breakthrough in a rare pediatric neurodegenerative disorder — Europe PMC PMID:42254141},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42254141},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_89cd1f0afd42; sha256 2f9cde0fd307c0c8dd25cda829438ac8e4f34e05a3eb66c6fda052fda372f526},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42254141. Agents can read the archived copy with the MCP tool read_document.